ZFIN ID: ZDB-PUB-120109-7
In vivo natriuretic peptide reporter assay identifies chemical modifiers of hypertrophic cardiomyopathy signaling
Becker, J.R., Robinson, T.Y., Sachidanandan, C., Kelly, A.E., Coy, S., Peterson, R.T., and MacRae, C.A.
Date: 2012
Source: Cardiovascular research   93(3): 463-470 (Journal)
Registered Authors: MacRae, Calum A., Peterson, Randall, Robinson, Tamara, Sachidanandan, Chetana
Keywords: none
MeSH Terms:
  • Animals
  • Animals, Genetically Modified
  • Butadienes/pharmacology
  • Cardiomyopathy, Hypertrophic/genetics*
  • Disease Models, Animal
  • Enzyme Inhibitors/pharmacology
  • Gene Expression Regulation, Developmental/physiology
  • Genes, Reporter/genetics
  • Genetic Markers/genetics*
  • Genetic Testing/methods*
  • Histone Deacetylase Inhibitors/pharmacology
  • Humans
  • Hydroxamic Acids/pharmacology
  • Luciferases/genetics*
  • Mammals
  • Natriuretic Peptides/genetics*
  • Natriuretic Peptides/metabolism
  • Nitriles/pharmacology
  • Signal Transduction/drug effects
  • Signal Transduction/genetics
  • Zebrafish/embryology
  • Zebrafish/genetics*
PubMed: 22198505 Full text @ Cardiovasc. Res.

Aims: Despite increased understanding of the fundamental biology regulating cardiomyocyte hypertrophy and heart failure, it has been challenging to find novel chemical or genetic modifiers of these pathways. Traditional cell-based methods do not model the complexity of an intact cardiovascular system and mammalian models are not readily adaptable to chemical or genetic screens. Our objective was to create an in vivo model suitable for chemical and genetic screens for hypertrophy and heart failure modifiers

Methods and Results: Using the developing zebrafish, we established that the cardiac natriuretic peptide genes (nppa and nppb), known markers of cardiomyocyte hypertrophy and heart failure, were induced in the embryonic heart by pathological cardiac stimuli. This pathological induction was distinct from the developmental regulation of these genes. We created a luciferase based transgenic reporter line that accurately modeled the pathological induction patterns of the zebrafish nppb gene. Utilizing this reporter line, we were able to show remarkable conservation of pharmacological responses between the larval zebrafish heart and adult mammalian models.

Conclusions: By performing a focused screen of chemical agents, we were able to show a distinct response of a genetic model of hypertrophic cardiomyopathy to the histone deacetylase inhibitor, Trichostatin A, and the mitogen activated protein kinase kinase 1/2 inhibitor, U0126. We believe this in vivo reporter line will offer a unique approach to the identification of novel chemical or genetic regulators of myocardial hypertrophy and heart failure.